Abstract
The use of platelet glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) is beneficial in patients with acute coronary syndromes (ACSs). Their benefit in the medical management of non-ST-segment elevation ACS has been less consistent. To assess the influence of the revascularization strategy on the effect …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
